Tadashi Kondo graduated from Okayama University Medical School, Okayama Prefecture, Japan, and obtained his M.D. degree in 1992. He studied proteomic backgrounds of aging and immortalization of human cells and obtained his Ph.D. degree in 1996. Dr. Kondo is currently the Chief of Division of Pharmacoproteomics at the National Cancer Center in Tokyo, Japan. He was committed to functional studies on the immortalization‐associated proteins at the Okayama University Medical School and extended his research to epigenomic backgrounds of hereditary disease and liver cancer at the University of Michigan, MI, USA. He launched cancer proteomics at National Cancer Center, in 2001. His research interests are mainly focused on translational cancer research toward personalized medicine by proteomic approach. Dr. Kondo discovered and validated several predictive and prognostic biomarkers in malignancies including hepatocellular carcinoma. He is an editor of seven international journals and an external reviewer of major research grants. He published more than 120 papers, obtained six patents about novel clinical utilities of cancer‐associated proteins, and received four prizes from domestic and international academic associations.
Biography Updated on 10 November 2016